Monitoring System For Vector-Based Influenza Vaccine

基于载体的流感疫苗监测系统

• 批准号: 7647452
• 负责人: MATTHEW M. FERRIS
• 金额: $ 80.94万
• 依托单位: INDEVR, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-07-01 至 2011-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7647452
• 关键词: Adenoviruses; Agreement; Algorithms; Area; Baculoviruses; Biological; Biological Assay; Bioreactors; Cell Culture Techniques; Computer software; Cost Savings; Cytomegalovirus; Data; Detection; Diagnostic; Dose; Electronics; Evaluation; Fermentation; Fluorescence; Health; Influenza; Liquid substance; Manuals; Manufacturer Name; Measurement; Medicine; Methods; Monitor; Optics; Performance; Phase; Plaque Assay; Proteins; Reagent; Recombinants; Research; Rubella; Sampling; Science; Scientist; Site; Small Business Innovation Research Grant; System; Technology; Testing; Time; Transmission Electron Microscopy; Vaccine Production; Vaccines; Viral Load result; Virus; Weight; base; college; combat; cost; cost effective; design; design and construction; expression vector; influenza virus vaccine; instrument; new technology; pandemic disease; prototype; public health relevance; response; success; tissue culture; tool; vaccine development; vector

DESCRIPTION (provided by applicant): This Phase II Advanced Technology SBIR [PA-06-134] proposal is in response to NIAID's Notice of High-Priority Influenza Research Areas [NOT-AI-05-013]. In order to provide health officials with the tools required to efficiently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. The proposed instrument is specifically designed to provide a rapid count of the number of "intact" viruses per unit volume in liquid. While optimization of vaccine production methods is an example application for which the number of intact viruses is a valuable measurement, the time and cost savings of virus enumeration within minutes, rather than days, is anticipated to have substantial impact on several other virus-related fields. Support for that outlook is provided by the excellent group of collaborators we have been able to assemble during the Phase I efforts, including scientists from two large vaccine manufacturers (MedImmune and Novartis), a small cutting-edge vaccine manufacturer (Protein Sciences Corporation), a biological reagents company (Microbix Biosystems, Inc.), a diagnostics company (Quidel Corporation), and a College of Medicine (at Baylor). All Phase I objectives were achieved and in many cases exceeded. During Phase II efforts we will i) design and construct an advanced prototype Virus CounterTM and develop automated methods for instrument parameter setup; ii) evaluate instrument performance in comparison with standard methods such as plaque assays, fluorescence focus assays, transmission electron microscopy and real-time quantitative PCR, iii) optimize the Virus CounterTM and assay for utility in vaccine production, and iv) conduct beta-site testing of the instrument. PUBLIC HEALTH RELEVANCE: In order to provide health officials with the tools required to efficiently combat a pandemic strain of influenza, it is essential that rapid and cost-effective methods for vaccine production be developed. The proposed instrument is specifically designed to provide a rapid count of the number of "intact" viruses per unit volume in liquid. While optimization of vaccine production methods is an example application for which the number of intact viruses is a valuable measurement, the time and cost savings of virus enumeration within minutes, rather than days, is anticipated to have substantial impact on several other virus-related fields.

描述（由申请人提供）：本第二阶段先进技术 SBIR [PA-06-134] 提案是对 NIAID 高优先级流感研究领域通知 [NOT-AI-05-013] 的回应。为了向卫生官员提供有效对抗流感大流行株所需的工具，必须开发快速且具有成本效益的疫苗生产方法。所提议的仪器专门设计用于快速计数液体中每单位体积的“完整”病毒数量。虽然疫苗生产方法的优化是一个示例应用，其中完整病毒的数量是一个有价值的衡量标准，但在几分钟而不是几天内进行病毒计数所节省的时间和成本预计将对其他几个病毒相关领域产生重大影响。我们在第一阶段工作中聚集的优秀合作者团队为这一前景提供了支持，其中包括来自两家大型疫苗制造商（MedImmune 和诺华）、一家小型尖端疫苗制造商（Protein Sciences Corporation）的科学家，一家生物试剂公司（Microbix Biosystems, Inc.）、一家诊断公司（Quidel Corporation）和一所医学院（位于贝勒）。第一阶段的所有目标均已实现，并且在许多情况下已超额完成。在第二阶段的工作中，我们将 i) 设计和构建先进的 Virus CounterTM 原型并开发仪器参数设置的自动化方法； ii) 与噬菌斑测定、荧光聚焦测定、透射电子显微镜和实时定量 PCR 等标准方法相比评估仪器性能，iii) 优化 Virus CounterTM 和测定在疫苗生产中的实用性，以及 iv) 进行 beta 位点分析仪器的测试。 公共卫生相关性：为了向卫生官员提供有效对抗大流行性流感病毒所需的工具，必须开发快速且具有成本效益的疫苗生产方法。所提议的仪器专门设计用于快速计数液体中每单位体积的“完整”病毒数量。虽然疫苗生产方法的优化是一个示例应用，其中完整病毒的数量是一个有价值的衡量标准，但在几分钟而不是几天内进行病毒计数所节省的时间和成本预计将对其他几个病毒相关领域产生重大影响。